Cargando…

Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

INTRODUCTION: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating...

Descripción completa

Detalles Bibliográficos
Autores principales: Makino, Katsuhiro, Nakata, Jumi, Kawachi, Satoru, Hayashi, Tatsuyuki, Nakajima, Atsuo, Yokoyama, Munehiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923559/
https://www.ncbi.nlm.nih.gov/pubmed/24377366
http://dx.doi.org/10.1186/1752-1947-7-280
_version_ 1782303625969664000
author Makino, Katsuhiro
Nakata, Jumi
Kawachi, Satoru
Hayashi, Tatsuyuki
Nakajima, Atsuo
Yokoyama, Munehiro
author_facet Makino, Katsuhiro
Nakata, Jumi
Kawachi, Satoru
Hayashi, Tatsuyuki
Nakajima, Atsuo
Yokoyama, Munehiro
author_sort Makino, Katsuhiro
collection PubMed
description INTRODUCTION: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating intravascular large B-cell lymphoma. However, adverse events have been reported in association with rituximab infusion. CASE PRESENTATION: We report the case of a 54-year-old Japanese man diagnosed with Asian variant intravascular large B-cell lymphoma who died within five hours of the initiation of a first course of chemotherapy including rituximab. Autopsy results suggested that the patient died of severe systemic inflammatory response syndrome. A literature review revealed that rituximab administered during the second course of chemotherapy (instead of during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering the frequency of complete remission outcomes. CONCLUSIONS: Our data indicate that the incidence of adverse reactions to rituximab can be markedly decreased if the tumor load is first reduced with an initial course of chemotherapy excluding rituximab. Future prospective studies of the timing of rituximab administration are warranted.
format Online
Article
Text
id pubmed-3923559
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39235592014-02-14 Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature Makino, Katsuhiro Nakata, Jumi Kawachi, Satoru Hayashi, Tatsuyuki Nakajima, Atsuo Yokoyama, Munehiro J Med Case Rep Case Report INTRODUCTION: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating intravascular large B-cell lymphoma. However, adverse events have been reported in association with rituximab infusion. CASE PRESENTATION: We report the case of a 54-year-old Japanese man diagnosed with Asian variant intravascular large B-cell lymphoma who died within five hours of the initiation of a first course of chemotherapy including rituximab. Autopsy results suggested that the patient died of severe systemic inflammatory response syndrome. A literature review revealed that rituximab administered during the second course of chemotherapy (instead of during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering the frequency of complete remission outcomes. CONCLUSIONS: Our data indicate that the incidence of adverse reactions to rituximab can be markedly decreased if the tumor load is first reduced with an initial course of chemotherapy excluding rituximab. Future prospective studies of the timing of rituximab administration are warranted. BioMed Central 2013-12-30 /pmc/articles/PMC3923559/ /pubmed/24377366 http://dx.doi.org/10.1186/1752-1947-7-280 Text en Copyright © 2013 Makino et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Makino, Katsuhiro
Nakata, Jumi
Kawachi, Satoru
Hayashi, Tatsuyuki
Nakajima, Atsuo
Yokoyama, Munehiro
Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
title Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
title_full Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
title_fullStr Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
title_full_unstemmed Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
title_short Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
title_sort treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large b-cell lymphoma: a case report and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923559/
https://www.ncbi.nlm.nih.gov/pubmed/24377366
http://dx.doi.org/10.1186/1752-1947-7-280
work_keys_str_mv AT makinokatsuhiro treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature
AT nakatajumi treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature
AT kawachisatoru treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature
AT hayashitatsuyuki treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature
AT nakajimaatsuo treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature
AT yokoyamamunehiro treatmentstrategyforreducingtheriskofrituximabinducedcytokinereleasesyndromeinpatientswithintravascularlargebcelllymphomaacasereportandreviewoftheliterature